Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

62.72 +0.81 (+1.31%)
Streaming Delayed Price Updated: 11:19 AM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
Upgrades For IGM Biosciences Inc (NASDAQ: 
Via Benzinga
Why Sarepta Therapeutics Shares Dropped More Than 16% This Week
The biotech stock fell a little more than $72 since its close last Friday. 
Via The Motley Fool
Analyst Ratings For Sarepta Therapeutics
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:... 
Via Benzinga
Sarepta Therapeutics (SRPT) Q3 2021 Earnings Call Transcript
SRPT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
Expert Ratings For Sarepta Therapeutics
Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ: 
Via Benzinga
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Is This Beaten Down Biotech a Bad News Buy?
It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look? 
Via The Motley Fool
Why Sarepta Therapeutics Fell 14.7% This Week
Investors were unimpressed by the company's clinical and financial news. 
Via The Motley Fool
50 Biggest Movers From Yesterday
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating... 
Via Benzinga
Why Sarepta Therapeutics Tumbled Today
Investors weren't wowed by a company update, or by news of a fresh stock issue. 
Via The Motley Fool
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7... 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
Exposures Product Safety
A Peek Into The Markets: US Stock Futures Gain Ahead Of CPI, Fed Minutes
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the Dow Jones dropped more than 100 points in the previous session. Investors are... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
5 Stocks To Watch For October 13, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects JPMorgan Chase & Co. (NYSE: JPM) to report quarterly earnings at $3.00 per share on revenue... 
Via Benzinga
What 5 Analyst Ratings Have To Say About Sarepta Therapeutics
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:... 
Via Benzinga
Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements
Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK... 
Via Benzinga
Sarepta, Codiak Nix Exosome Therapy Development Pact
Sarepta Therapeutics Inc (NASDAQ: SRPT) notified Codiak BioSciences Inc (NASDAQ: CDAK) that it would terminate the two-year Research License and Option... 
Via Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2021
Upgrades For Alcoa Corp (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
Gene therapy is set to become one of the most vital spaces with high prospects in the biotech sector. 
Via Talk Markets
The Latest Barron's Picks And Pans Include General Electric, Netflix, Reddit And More
This weekend's Barron's reveals what market strategists recommend for a stock market that likely will struggle this fall. Other featured articles discuss biotech stocks... 
Via Benzinga
'Fast Money Halftime Report' Picks For August 24
On CNBC's "Fast Money Halftime Report," Stephanie Link said Aptiv PLC (NYSE: APTV) is worthy of a buy. Jon Najarian bought Sarepta Therapeutics Inc (NASDAQ: SRPT) on... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021
Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ: 
Via Benzinga
99 Biggest Movers From Yesterday
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
Sarepta Therapeutics (SRPT) Q2 2021 Earnings Call Transcript
SRPT earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS